AstraZeneca B.V.
AstraZeneca B.V., a prominent player in the global pharmaceutical industry, is headquartered in the Netherlands (NL) and operates extensively across Europe, North America, and Asia. Founded in 1999 through the merger of Astra AB and Zeneca Group, the company has achieved significant milestones, including advancements in oncology, cardiovascular, and respiratory therapies. AstraZeneca is renowned for its innovative core products, such as the cancer treatment Tagrisso and the COVID-19 vaccine Vaxzevria, which highlight its commitment to addressing critical health challenges. With a strong market position, AstraZeneca consistently ranks among the top pharmaceutical companies worldwide, driven by a robust pipeline of research and development initiatives. The company's dedication to scientific excellence and patient-centric solutions sets it apart in the competitive landscape of biopharmaceuticals.
DitchCarbon Score
How does AstraZeneca B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AstraZeneca B.V.'s score of 53 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AstraZeneca B.V.'s reported carbon emissions
AstraZeneca B.V., headquartered in the Netherlands, currently does not provide specific carbon emissions data for the most recent year, as no emissions figures are available. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the absence of specific emissions data, it is important to note that AstraZeneca operates within an industry increasingly focused on sustainability and climate action. Many pharmaceutical companies are committing to reducing their carbon footprints and enhancing their environmental performance. AstraZeneca's commitment to addressing climate change may align with broader industry trends, including the adoption of science-based targets and initiatives aimed at achieving net-zero emissions in the future. As the company progresses in its sustainability journey, stakeholders can expect potential future disclosures regarding emissions and climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AstraZeneca B.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
